In Defense Of “Me-Too” Drugs: Is Primary Care Losing Out To Rare Disease R&D?
This article was originally published in RPM Report
Regulatory and financial incentives have sparked major investment in orphan drug development. One-third of the new molecular entities and novel biologics approved by FDA in the past five years have been orphan drugs. But now some stakeholders are questioning whether the focus on orphans is orphaning another market: primary care conditions that are still not adequately treated. Are incentives needed?
You may also be interested in...
US FDA Commissioner Gottlieb says common diseases need new treatments and argues streamlining trials may pique industry interest.
Since being promoted to chief scientific officer of Bristol-Myers Squibb, effective July 2013, company veteran Francis Cuss says he has aimed for continuity while staying flexible to respond to breaking science. In an interview at the J.P. Morgan Healthcare Conference in January, he explains the company’s thinking when it comes to focusing on particular disease areas with the highest unmet need and potential for speedy development.
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.